Table of Contents Author Guidelines Submit a Manuscript
Pain Research and Management
Volume 2018, Article ID 1630709, 11 pages
https://doi.org/10.1155/2018/1630709
Review Article

Gaps in Understanding Mechanism and Lack of Treatments: Potential Use of a Nonhuman Primate Model of Oxaliplatin-Induced Neuropathic Pain

1Hamamatsu Pharma Research, Inc., Hamamatsu, Shizuoka 431-2103, Japan
2Human Informatics Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8568, Japan
3Hamamatsu Pharma Research USA, Inc., San Diego, CA 92122, USA

Correspondence should be addressed to Aldric Hama; pj.amrahph@amah-cirdla

Received 21 February 2018; Accepted 3 April 2018; Published 2 May 2018

Academic Editor: Ulises Coffeen

Copyright © 2018 Aldric Hama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Heide, H. Bostock, L. Ventzel et al., “Axonal excitability changes and acute symptoms of oxaliplatin treatment: in vivo evidence for slowed sodium channel inactivation,” Clinical Neurophysiology, vol. 129, no. 3, pp. 694–706, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. D. R. Pachman, R. Qin, D. K. Seisler et al., “Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance),” Journal of Clinical Oncology, vol. 33, no. 30, pp. 3416–3422, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Hartemann, N. Attal, D. Bouhassira et al., “Painful diabetic neuropathy: diagnosis and management,” Diabetes and Metabolism, vol. 37, no. 5, pp. 377–388, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Cascella, “Chemotherapy-induced peripheral neuropathy: limitations in current prophylactic strategies and directions for future research,” Current Medical Research and Opinion, vol. 33, no. 6, pp. 981–984, 2017. View at Publisher · View at Google Scholar · View at Scopus
  5. S. B. Park, D. Goldstein, A. V. Krishnan et al., “Chemotherapy-induced peripheral neurotoxicity: a critical analysis,” CA: A Cancer Journal for Clinicians, vol. 63, no. 6, pp. 419–437, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Ewertz, C. Qvortrup, and L. Eckhoff, “Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives,” Acta Oncologica, vol. 54, no. 5, pp. 587–591, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Grisold, G. Cavaletti, and A. J. Windebank, “Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention,” Neuro-Oncology, vol. 14, no. 4, p. iv45, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. A. A. Argyriou, A. P. Kyritsis, T. Makatsoris, and H. Kalofonos, “Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature,” Cancer Management and Research, vol. 6, pp. 135–147, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. N. C. Miltenburg and W. Boogerd, “Chemotherapy-induced neuropathy: a comprehensive survey,” Cancer Treatment Reviews, vol. 40, no. 7, pp. 872–882, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. M. de Carvalho Barbosa, A. K. Kosturakis, C. Eng et al., “A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy,” Cancer Research, vol. 74, no. 21, pp. 5955–5962, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Yin, K. Zimmermann, I. Vetter, and R. J. Lewis, “Therapeutic opportunities for targeting cold pain pathways,” Biochemical Pharmacology, vol. 93, no. 2, pp. 125–140, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Starobova and I. Vetter, “Pathophysiology of chemotherapy-induced peripheral neuropathy,” Frontiers in Molecular Neuroscience, vol. 10, p. 174, 2017. View at Publisher · View at Google Scholar · View at Scopus
  13. Food and Drug Administration, Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD, USA, 2005.
  14. L. M. Alejandro, C. E. Behrendt, K. Chen, H. Openshaw, and S. Shibata, “Predicting acute and persistent neuropathy associated with oxaliplatin,” American Journal of Clinical Oncology, vol. 36, no. 4, pp. 331–337, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. G. D. Leonard, M. A. Wright, M. G. Quinn et al., “Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer,” BMC Cancer, vol. 5, no. 1, p. 116, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Attal, D. Bouhassira, M. Gautron et al., “Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study,” Pain, vol. 144, no. 3, pp. 245–252, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Baron, G. Haendler, and H. Schulte, “Afferent large fiber polyneuropathy predicts the development of postherpetic neuralgia,” Pain, vol. 73, no. 2, pp. 231–238, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. A. E. Golshani, A. A. Kamdar, S. C. Spence, and N. Beckmann, “Congenital indifference to pain: an illustrated case report and literature review,” Journal of Radiology Case Reports, vol. 8, no. 8, pp. 16–23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. N. J. Spencer, V. Zagorodnyuk, S. J. Brookes, and T. Hibberd, “Spinal afferent nerve endings in visceral organs: recent advances,” American Journal of Physiology Gastrointestinal and Liver Physiology, vol. 311, no. 6, pp. G1056–G1063, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. M. J. Millan, “The induction of pain: an integrative review,” Progress in Neurobiology, vol. 57, no. 1, pp. 1–164, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. A. I. Basbaum and T. N. Jessell, “Pain,” in Principles of Neural Science, E. R. Kandel, Ed., pp. 530–553, McGraw Hill, New York, NY, USA, 2013. View at Google Scholar
  22. C. Lu, T. Yang, H. Zhao et al., “Insular cortex is critical for the perception, modulation, and chronification of pain,” Neuroscience Bulletin, vol. 32, no. 2, pp. 191–201, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. C. E. Wilcox, A. R. Mayer, T. M. Teshiba et al., “The subjective experience of pain: an FMRI study of percept-related models and functional connectivity,” Pain Medicine, vol. 16, no. 11, pp. 2121–2133, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. M. G. Liu and J. Chen, “Roles of the hippocampal formation in pain information processing,” Neuroscience Bulletin, vol. 25, no. 5, pp. 237–266, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. S. Jaggi and N. Singh, “Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy,” Toxicology, vol. 291, no. 1–3, pp. 1–9, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Authier, D. Balayssac, F. Marchand et al., “Animal models of chemotherapy-evoked painful peripheral neuropathies,” Neurotherapeutics, vol. 6, no. 4, pp. 620–629, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. M. Verdier, I. Acquatella, C. Lautier et al., “Lessons from the analysis of nonhuman primates for understanding human aging and neurodegenerative diseases,” Frontiers in Neuroscience, vol. 9, p. 64, 2015. View at Google Scholar
  28. J. Chen, D. Kang, J. Xu et al., “Species differences and molecular determinant of TRPA1 cold sensitivity,” Nature Communications, vol. 4, p. 2501, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Han, M. Estacion, J. Huang et al., “Human Na(v)1.8: enhanced persistent and ramp currents contribute to distinct firing properties of human DRG neurons,” Journal of Neurophysiology, vol. 113, no. 9, pp. 3172–3185, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. J. P. Capitanio and M. E. Emborg, “Contributions of non-human primates to neuroscience research,” The Lancet, vol. 371, no. 9618, pp. 1126–1135, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Teo, J. V. Rosenfeld, and J. A. Bourne, “Models of CNS injury in the nonhuman primate: a new era for treatment strategies,” Translational Neuroscience, vol. 3, no. 2, pp. 181–195, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Courtine, M. B. Bunge, J. W. Fawcett et al., “Can experiments in nonhuman primates expedite the translation of treatments for spinal cord injury in humans?” Nature Medicine, vol. 13, no. 5, pp. 561–566, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Hama and H. Takamatsu, “Chemotherapy-induced peripheral neuropathic pain and rodent models,” CNS and Neurological Disorders Drug Targets, vol. 15, no. 1, pp. 7–19, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. K. D. Davis, Z. H. Kiss, R. R. Tasker, and J. O. Dostrovsky, “Thalamic stimulation-evoked sensations in chronic pain patients and in nonpain (movement disorder) patients,” Journal of Neurophysiology, vol. 75, no. 3, pp. 1026–1037, 1996. View at Publisher · View at Google Scholar
  35. J. L. Parker, D. M. Karantonis, P. S. Single, M. Obradovic, and M. J. Cousins, “Compound action potentials recorded in the human spinal cord during neurostimulation for pain relief,” Pain, vol. 153, no. 3, pp. 593–601, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Falci, L. Best, R. Bayles, D. Lammertse, and C. Starnes, “Dorsal root entry zone microcoagulation for spinal cord injury-related central pain: operative intramedullary electrophysiological guidance and clinical outcome,” Journal of Neurosurgery, vol. 97, no. 2, pp. 193–200, 2002. View at Publisher · View at Google Scholar
  37. J. Upadhyay, J. Anderson, A. J. Schwarz et al., “Imaging drugs with and without clinical analgesic efficacy,” Neuropsychopharmacology, vol. 36, no. 13, pp. 2659–2673, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. S. M. Smith, R. H. Dworkin, D. C. Turk et al., “The potential role of sensory testing, skin biopsy, and functional brain imaging as biomarkers in chronic pain clinical trials: IMMPACT considerations,” Journal of Pain, vol. 18, no. 7, pp. 757–777, 2017. View at Publisher · View at Google Scholar · View at Scopus
  39. M. C. Reddan and T. D. Wager, “Modeling pain using fMRI: from regions to biomarkers,” Neuroscience Bulletin, vol. 34, no. 1, pp. 208–215, 2018. View at Publisher · View at Google Scholar · View at Scopus
  40. U. Friebel, S. B. Eickhoff, and M. Lotze, “Coordinate-based meta-analysis of experimentally induced and chronic persistent neuropathic pain,” Neuroimage, vol. 58, no. 4, pp. 1070–1080, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. E. G. Boland, D. Selvarajah, M. Hunter et al., “Central pain processing in chronic chemotherapy-induced peripheral neuropathy: a functional magnetic resonance imaging study,” PLoS One, vol. 9, no. 5, Article ID e96474, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Nagasaka, K. Yamanaka, S. Ogawa, H. Takamatsu, and N. Higo, “Brain activity changes in a macaque model of oxaliplatin-induced neuropathic cold hypersensitivity,” Scientific Reports, vol. 7, no. 1, p. 4305, 2017. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Shidahara, S. Ogawa, M. Nakamura et al., “Pharmacological comparison of a nonhuman primate and a rat model of oxaliplatin-induced neuropathic cold hypersensitivity,” Pharmacology Research and Perspectives, vol. 4, no. 1, p. e00216, 2016. View at Publisher · View at Google Scholar · View at Scopus
  44. B. Ling, F. Coudore, L. Decalonne, A. Eschalier, and N. Authier, “Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection,” Neuropharmacology, vol. 55, no. 5, pp. 724–728, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Zhao, S. Nakamura, T. Miyake et al., “Pharmacological characterization of standard analgesics on oxaliplatin-induced acute cold hypersensitivity in mice,” Journal of Pharmacological Sciences, vol. 124, no. 4, pp. 514–517, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. E. M. Smith, H. Pang, C. Cirrincione et al., “Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial,” Journal of the American Medical Association, vol. 309, no. 13, pp. 1359–1367, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. D. C. de Andrade, M. Jacobsen Teixeira, R. Galhardoni et al., “Pregabalin for the prevention of oxaliplatin-induced painful neuropathy: a randomized, double-blind trial,” Oncologist, vol. 22, no. 10, pp. 1154–e1105, 2017. View at Publisher · View at Google Scholar · View at Scopus
  48. E. Peltz, F. Seifert, R. DeCol, A. Dörfler, S. Schwab, and C. Maihöfner, “Functional connectivity of the human insular cortex during noxious and innocuous thermal stimulation,” Neuroimage, vol. 54, no. 2, pp. 1324–1335, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. L. M. Chen, “Cortical representation of pain and touch: evidence from combined functional neuroimaging and electrophysiology in non-human primates,” Neuroscience Bulletin, vol. 34, no. 1, pp. 165–177, 2018. View at Publisher · View at Google Scholar · View at Scopus
  50. V. Wanigasekera, K. Wartolowska, J. P. Huggins et al., “Disambiguating pharmacological mechanisms from placebo in neuropathic pain using functional neuroimaging,” British Journal of Anaesthesia, vol. 120, no. 2, pp. 299–307, 2018. View at Publisher · View at Google Scholar
  51. F. Seifert and C. Maihofner, “Central mechanisms of experimental and chronic neuropathic pain: findings from functional imaging studies,” Cellular and Molecular Life Sciences, vol. 66, no. 3, pp. 375–390, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Peyron, “Functional brain imaging: what has it brought to our understanding of neuropathic pain? A special focus on allodynic pain mechanisms,” Pain, vol. 157, no. 1, pp. S67–S71, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Natsume, S. Ogawa, Y. Awaga et al., “Brain activation in a nonhuman primate model of oxaliplatin-induced peripheral neuropathy: suppression with duloxetine,” in Proceedings of the 11th Annual Pain and Migraine Therapeutics Summit, Arrowhead Publishers, San Diego, CA, USA, October 2017.
  54. D. L. Hershman, C. Lacchetti, R. H. Dworkin et al., “Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline,” Journal of Clinical Oncology, vol. 32, no. 18, pp. 1941–1967, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. N. Majithia, S. M. Temkin, K. J. Ruddy, A. S. Beutler, D. L. Hershman, and C. L. Loprinzi, “National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons,” Supportive Care in Cancer, vol. 24, no. 3, pp. 1439–1447, 2016. View at Publisher · View at Google Scholar · View at Scopus
  56. S. S. Jacobs, E. Fox, C. Dennie et al., “Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates,” Clinical Cancer Research, vol. 11, no. 4, pp. 1669–1674, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Canta, E. Pozzi, and V. A. Carozzi, “Mitochondrial dysfunction in chemotherapy-induced peripheral neuropathy (CIPN),” Toxics, vol. 3, no. 2, pp. 198–223, 2015. View at Publisher · View at Google Scholar
  58. N. Kerckhove, A. Collin, S. Conde, C. Chaleteix, D. Pezet, and D. Balayssac, “Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review,” Frontiers in Pharmacology, vol. 8, p. 86, 2017. View at Publisher · View at Google Scholar · View at Scopus
  59. L. E. Ta, L. Espeset, J. Podratz, and A. J. Windebank, “Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding,” Neurotoxicology, vol. 27, no. 6, pp. 992–1002, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. M. J. McKeage, T. Hsu, D. Screnci et al., “Nucleolar damage correlates with neurotoxicity induced by different platinum drugs,” British Journal of Cancer, vol. 85, no. 8, pp. 1219–1225, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Zheng, W. H. Xiao, and G. J. Bennett, “Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy,” Experimental Neurology, vol. 232, no. 2, pp. 154–161, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. W. H. Xiao, H. Zheng, and G. J. Bennett, “Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel,” Neuroscience, vol. 203, pp. 194–206, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. U. Anand, W. R. Otto, and P. Anand, “Sensitization of capsaicin and icilin responses in oxaliplatin treated adult rat DRG neurons,” Molecular Pain, vol. 6, p. 82, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. M. A. Graham, G. F. Lockwood, D. Greenslade et al., “Clinical pharmacokinetics of oxaliplatin: a critical review,” Clinical Cancer Research, vol. 6, pp. 1205–1218, 2000. View at Google Scholar
  65. S. Toyama, N. Shimoyama, Y. Ishida, T. Koyasu, H. H. Szeto, and M. Shimoyama, “Characterization of acute and chronic neuropathies induced by oxaliplatin in mice and differential effects of a novel mitochondria-targeted antioxidant on the neuropathies,” Anesthesiology, vol. 120, no. 2, pp. 459–473, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Cavaletti, G. Tredici, M. G. Petruccioli et al., “Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat,” European Journal of Cancer, vol. 37, no. 18, pp. 2457–2463, 2001. View at Publisher · View at Google Scholar · View at Scopus
  67. L. Apostolidis, D. Schwarz, A. Xia et al., “Dorsal root ganglia hypertrophy as in vivo correlate of oxaliplatin-induced polyneuropathy,” PLoS One, vol. 12, no. 8, Article ID e0183845, 2017. View at Publisher · View at Google Scholar · View at Scopus
  68. M. A. Geyer and A. Markou, “Animal models of psychiatric disorders,” in Psychopharmacology: The Fourth Generation of Progress, F. E. Bloom and D. J. Kupfer, Eds., pp. 787–798, Raven Press, New York, NY, USA, 1995. View at Google Scholar
  69. E. K. Joseph, X. Chen, O. Bogen, and J. D. Levine, “Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy,” Journal of Pain, vol. 9, no. 5, pp. 463–472, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. J. R. Deuis, Y. L. Lim, S. Rodrigues de Sousa et al., “Analgesic effects of clinically used compounds in novel mouse models of polyneuropathy induced by oxaliplatin and cisplatin,” Neuro-Oncology, vol. 16, no. 10, pp. 1324–1332, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Adelsberger, S. Quasthoff, J. Grosskreutz, A. Lepier, F. Eckel, and C. Lersch, “The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons,” European Journal of Pharmacology, vol. 406, no. 1, pp. 25–32, 2000. View at Publisher · View at Google Scholar · View at Scopus
  72. C. P. Taylor and L. S. Narasimhan, “Sodium channels and therapy of central nervous system diseases,” Advances in Pharmacology, vol. 39, pp. 47–98, 1997. View at Publisher · View at Google Scholar · View at Scopus
  73. R. G. Webster, K. L. Brain, R. H. Wilson, J. L. Grem, and A. Vincent, “Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels,” British Journal of Pharmacology, vol. 146, no. 7, pp. 1027–1039, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. R. H. Wilson, T. Lehky, R. R. Thomas et al., “Acute oxaliplatin-induced peripheral nerve hyperexcitability,” Journal of Clinical Oncology, vol. 20, no. 16, pp. 1767–1774, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. B. Ling, N. Authier, D. Balayssac et al., “Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat,” Pain, vol. 128, no. 3, pp. 225–234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. C. Lersch, R. Schmelz, F. Eckel et al., “Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer,” Clinical Colorectal Cancer, vol. 2, no. 1, pp. 54–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  77. S. von Delius, F. Eckel, S. Wagenpfeil et al., “Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study,” Investigational New Drugs, vol. 25, no. 2, pp. 173–180, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. T. J. Lehky, G. D. Leonard, R. H. Wilson, J. L. Grem, and M. K. Floeter, “Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy,” Muscle and Nerve, vol. 29, no. 3, pp. 387–392, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. S. A. S. van den Heuvel, S. E. I. van der Wal, L. A. Smedes et al., “Intravenous lidocaine: old-school drug, new purpose-reduction of intractable pain in patients with chemotherapy induced peripheral neuropathy,” Pain Research and Management, vol. 2017, Article ID 8053474, 9 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  80. R. Baron, M. Allegri, G. Correa-Illanes et al., “The 5% lidocaine-medicated plaster: its inclusion in international treatment guidelines for treating localized neuropathic pain, and clinical evidence supporting its use,” Pain Therapeutics, vol. 5, no. 2, pp. 149–169, 2016. View at Publisher · View at Google Scholar
  81. N. A. Hagen, L. Cantin, J. Constant et al., “Tetrodotoxin for moderate to severe cancer-related pain: a multicentre, randomized, double-blind, placebo-controlled, parallel-design trial,” Pain Research and Management, vol. 2017, Article ID 7212713, 7 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  82. J. M. Chung and K. Chung, “Sodium channels and neuropathic pain,” in Pathological Pain: From Molecular to Clinical Aspects, D. J. Chadwick and J. Goode, Eds., vol. 261, pp. 19–27, Chichester, UK, John Wiley & Sons, 2004. View at Google Scholar
  83. M. Naziroglu and N. Braidy, “Thermo-sensitive TRP channels: novel targets for treating chemotherapy-induced peripheral pain,” Frontiers in Physiology, vol. 8, p. 1040, 2017. View at Publisher · View at Google Scholar · View at Scopus
  84. W. M. Knowlton, R. L. Daniels, R. Palkar, D. D. McCoy, and D. D. McKemy, “Pharmacological blockade of TRPM8 ion channels alters cold and cold pain responses in mice,” PLoS One, vol. 6, no. 9, Article ID e25894, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. T. Nakagawa and S. Kaneko, “Roles of transient receptor potential ankyrin 1 in oxaliplatin-induced peripheral neuropathy,” Biological and Pharmaceutical Bulletin, vol. 40, no. 7, pp. 947–953, 2017. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Dhopeshwarkar and K. Mackie, “CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?” Molecular Pharmacology, vol. 86, no. 4, pp. 430–437, 2014. View at Publisher · View at Google Scholar · View at Scopus
  87. P. G. Blanchard and V. Luu-The, “Differential androgen and estrogen substrates specificity in the mouse and primates type 12 17beta-hydroxysteroid dehydrogenase,” Journal of Endocrinology, vol. 194, no. 2, pp. 449–455, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Ogawa, Y. Awaga, M. Takashima, A. Hama, A. Matsuda, and H. Takamatsu, “Antinociceptive effect of clinical analgesics in a nonhuman primate model of knee osteoarthritis,” European Journal of Pharmacology, vol. 786, pp. 179–185, 2016. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Ogawa, Y. Awaga, M. Takashima, A. Hama, A. Matsuda, and H. Takamatsu, “Knee osteoarthritis pain following medial meniscectomy in the nonhuman primate,” Osteoarthritis and Cartilage, vol. 24, no. 7, pp. 1190–1199, 2016. View at Publisher · View at Google Scholar · View at Scopus
  90. J. Chen and D. H. Hackos, “TRPA1 as a drug target–promise and challenges,” Naunyn-Schmiedeberg’s Archives of Pharmacology, vol. 388, no. 4, pp. 451–463, 2015. View at Publisher · View at Google Scholar · View at Scopus
  91. W. J. Winchester, K. Gore, S. Glatt et al., “Inhibition of TRPM8 channels reduces pain in the cold pressor test in humans,” Journal of Pharmacology and Experimental Therapeutics, vol. 351, no. 2, pp. 259–269, 2014. View at Publisher · View at Google Scholar · View at Scopus
  92. A. D. Weyer and S. G. Lehto, “Development of TRPM8 antagonists to treat chronic pain and migraine,” Pharmaceuticals, vol. 10, no. 4, p. 37, 2017. View at Publisher · View at Google Scholar · View at Scopus
  93. H. Ohshiro, A. Fujiuchi, A. Yamada et al., “In vitro and in vivo characterization of RQ-00434739, a novel orally active and selective trpm8 antagonist for the treatment of oxaliplatin-induced peripheral neuropathic pain,” in Proceedings of the 16th World Congress on Pain, Yokohama, Japan, September 2016.
  94. M. Sakurai, N. Egashira, T. Kawashiri, T. Yano, H. Ikesue, and R. Oishi, “Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia,” Pain, vol. 147, no. 1, pp. 165–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. D. J. Storey, L. A. Colvin, M. J. Mackean et al., “Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery,” Journal of Pain and Symptom Management, vol. 39, no. 6, pp. e2–e4, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. C. H. Wong, K. W. Siah, and A. W. Lo, “Estimation of clinical trial success rates and related parameters,” Biostatistics, 2018, In press. View at Google Scholar